Spun out of Northwestern University, Rhaeos, Inc. is a clinical stage medical device company developing FlowSense, a patent-protected platform technology and a non-invasive wireless, wearable skin patch that can assess and monitor fluid flow sub-dermally throughout the body. With a focus on improving the care of those suffering from chronic and difficult-to-treat conditions, the company initially is targeting hydrocephalus, a life threatening condition caused by an abnormal accumulation of cerebrospinal fluid (CSF). Implantable shunts, the gold standard treatment, often fail, leading to multiple trips to the emergency room and repeat surgeries. There has not previously been any technology available able easily to assess CSF flow in shunts wirelessly, bedside, and without capital equipment.
